10 Best Performing Healthcare Stocks So Far in 2026 

Page 4 of 4

6. AnaptysBio, Inc. (NASDAQ:ANAB)

YTD Share Price Gain: 131.2%

AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks Biotherapeutics (TRAX) spinoff, and thus now operates as a royalty management company, exclusively responsible for its financial collaborations with GSK and Vanda Pharmaceuticals.

Ultimately, Piper Sandler stated that it believes the separation makes sense, as it effectively works to protect and optimize the value of the royalty business. This is fundamentally distinct from the biopharma development company.

In another development, AnaptysBio, Inc. (NASDAQ:ANAB) announced on April 24 that the Delaware Chancery Court has dismissed Tesaro’s anticipatory breach of contract claim against the company, with the ruling agreeing with Anaptys’ position that it has never repudiated the Collaboration and Exclusive License Agreement with Tesaro regarding the development and commercialization of Jemperli. Tesaro is a subsidiary of GSK.

AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company that exclusively manages the financial collaborations from Jemperli with GSK and imsidolimab with Vanda.

While we acknowledge the potential of ANAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ANAB and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 Best Performing Healthcare Stocks So Far in 2026.

Disclosure: None. Follow Insider Monkey on Google News.

Page 4 of 4